Farnesyltransferase inhibitors: targeting the molecular basis of cancer
- 19 May 1999
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1423 (3), C19-C30
- https://doi.org/10.1016/s0304-419x(99)00007-4
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICSAnnual Review of Pharmacology and Toxicology, 1997
- ras Proto-Oncogene Activation in Human MalignancyPublished by Springer Nature ,1995
- Pharmaceutical research in molecular oncologyCell, 1994
- FUNCTION AND REGULATION OF RASAnnual Review of Biochemistry, 1993
- Human Sos1: a Guanine Nucleotide Exchange Factor for Ras that Binds to GRB2Science, 1993
- Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.Proceedings of the National Academy of Sciences, 1992
- Regulators and Effectors of ras ProteinsAnnual Review of Cell Biology, 1991
- Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivoCell, 1987
- Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virusNature, 1980
- Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistryCell, 1980